Do analysts rate HEPA or CASI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hepion Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 CASI Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend NXTS or HEPA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nexentis Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Hepion Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is NXTS or HEPA more profitable?

Nexentis Technologies' return on equity of -304.79% beat Hepion Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Nexentis Technologies N/A -304.79% -178.91% Hepion Pharmaceuticals N/A -812.56% -207.31%

Which has better valuation & earnings, ATXI or HEPA?

Avenue Therapeutics is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avenue Therapeutics N/A N/A -$10.38M -$0.85 N/A Hepion Pharmaceuticals N/A N/A -$48.93M -$72.15 N/A

Is ATXI or HEPA more profitable?

Avenue Therapeutics' return on equity of -471.57% beat Hepion Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Avenue Therapeutics N/A -471.57% -296.50% Hepion Pharmaceuticals N/A -812.56% -207.31%

Do analysts rate JAGX or HEPA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jaguar Animal Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Hepion Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Hepion Pharmaceuticals (HEPA) Competitors

$0.07 -0.01 (-14.56%)

As of 09/16/2026 02:35 PM Eastern

Compare

HEPA vs. CASI, NXTS, ORGS, ATXI, and JAGX

Should you buy Hepion Pharmaceuticals stock or one of its competitors? Hepion Pharmaceuticals's main competitors and comparable companies include CASI Pharmaceuticals (CASI), Nexentis Technologies (NXTS), Orgenesis (ORGS), Avenue Therapeutics (ATXI), and Jaguar Animal Health (JAGX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Hepion Pharmaceuticals compare to CASI Pharmaceuticals?

Hepion Pharmaceuticals (NASDAQ:HEPA) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hepion Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

17.2% of Hepion Pharmaceuticals shares are held by institutional investors. Comparatively, 22.2% of CASI Pharmaceuticals shares are held by institutional investors. 0.1% of Hepion Pharmaceuticals shares are held by insiders. Comparatively, 21.2% of CASI Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

CASI Pharmaceuticals has higher revenue and earnings than Hepion Pharmaceuticals. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A

In the previous week, Hepion Pharmaceuticals' average media sentiment score of 0.00 equaled CASI Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Hepion Pharmaceuticals	Neutral
CASI Pharmaceuticals	Neutral

Hepion Pharmaceuticals has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market. Comparatively, CASI Pharmaceuticals has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market.

Hepion Pharmaceuticals has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. CASI Pharmaceuticals' return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%
CASI Pharmaceuticals	-183.93%	N/A	-131.54%

Summary

CASI Pharmaceuticals beats Hepion Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

How does Hepion Pharmaceuticals compare to Nexentis Technologies?

Nexentis Technologies (NASDAQ:NXTS) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings.

Nexentis Technologies has higher revenue and earnings than Hepion Pharmaceuticals. Nexentis Technologies is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexentis Technologies	$210K	9.46	-$4M	-$96.07	N/A
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A

61.2% of Nexentis Technologies shares are owned by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. 6.5% of Nexentis Technologies shares are owned by insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Nexentis Technologies' return on equity of -304.79% beat Hepion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nexentis Technologies	N/A	-304.79%	-178.91%
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexentis Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Hepion Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Nexentis Technologies has a beta of 1.85, suggesting that its share price is 85% more volatile than the broader market. Comparatively, Hepion Pharmaceuticals has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market.

In the previous week, Nexentis Technologies had 2 more articles in the media than Hepion Pharmaceuticals. MarketBeat recorded 2 mentions for Nexentis Technologies and 0 mentions for Hepion Pharmaceuticals. Nexentis Technologies' average media sentiment score of 0.94 beat Hepion Pharmaceuticals' score of 0.00 indicating that Nexentis Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Nexentis Technologies	Positive
Hepion Pharmaceuticals	Neutral

Summary

Nexentis Technologies beats Hepion Pharmaceuticals on 11 of the 12 factors compared between the two stocks.

How does Hepion Pharmaceuticals compare to Orgenesis?

Orgenesis (NASDAQ:ORGS) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

Orgenesis has a beta of 3.16, suggesting that its stock price is 216% more volatile than the broader market. Comparatively, Hepion Pharmaceuticals has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market.

In the previous week, Orgenesis' average media sentiment score of 0.00 equaled Hepion Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Orgenesis	Neutral
Hepion Pharmaceuticals	Neutral

22.6% of Orgenesis shares are owned by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. 1.9% of Orgenesis shares are owned by company insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Hepion Pharmaceuticals has lower revenue, but higher earnings than Orgenesis. Orgenesis is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orgenesis	$662K	4.61	-$55.36M	-$11.51	N/A
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A

Hepion Pharmaceuticals has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orgenesis	-3,827.81%	N/A	-130.18%
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%

Summary

Orgenesis beats Hepion Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

How does Hepion Pharmaceuticals compare to Avenue Therapeutics?

Avenue Therapeutics (NASDAQ:ATXI) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Avenue Therapeutics' return on equity of -471.57% beat Hepion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avenue Therapeutics	N/A	-471.57%	-296.50%
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%

In the previous week, Avenue Therapeutics' average media sentiment score of 0.00 equaled Hepion Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Avenue Therapeutics	Neutral
Hepion Pharmaceuticals	Neutral

Avenue Therapeutics is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.85	N/A
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A

17.3% of Avenue Therapeutics shares are held by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are held by institutional investors. 8.6% of Avenue Therapeutics shares are held by company insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Avenue Therapeutics has a beta of -0.18, meaning that its share price is 118% less volatile than the broader market. Comparatively, Hepion Pharmaceuticals has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market.

Summary

Avenue Therapeutics beats Hepion Pharmaceuticals on 6 of the 8 factors compared between the two stocks.

How does Hepion Pharmaceuticals compare to Jaguar Animal Health?

Jaguar Animal Health (NASDAQ:JAGX) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

In the previous week, Jaguar Animal Health had 3 more articles in the media than Hepion Pharmaceuticals. MarketBeat recorded 3 mentions for Jaguar Animal Health and 0 mentions for Hepion Pharmaceuticals. Hepion Pharmaceuticals' average media sentiment score of 0.00 beat Jaguar Animal Health's score of -0.22 indicating that Hepion Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Jaguar Animal Health	Neutral
Hepion Pharmaceuticals	Neutral

Hepion Pharmaceuticals has lower revenue, but higher earnings than Jaguar Animal Health. Jaguar Animal Health is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jaguar Animal Health	$11.51M	0.10	-$53.43M	-$248.88	N/A
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A

12.0% of Jaguar Animal Health shares are held by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are held by institutional investors. 0.2% of Jaguar Animal Health shares are held by company insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jaguar Animal Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Hepion Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Jaguar Animal Health has a beta of -0.07, meaning that its stock price is 107% less volatile than the broader market. Comparatively, Hepion Pharmaceuticals has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market.

Hepion Pharmaceuticals has a net margin of 0.00% compared to Jaguar Animal Health's net margin of -187.88%. Jaguar Animal Health's return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jaguar Animal Health	-187.88%	N/A	-131.45%
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%

Summary

Jaguar Animal Health beats Hepion Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Get Hepion Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HEPA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HEPA vs. The Competition

Export

Metric	Hepion Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$772K	$12.53B	$7.22B	$14.93B
Dividend Yield	N/A	2.64%	2.57%	12.31%
P/E Ratio	-0.02	792.19	273.52	25.33
Price / Sales	N/A	758.12	647.05	87.33
Price / Cash	N/A	85.42	76.40	50.90
Price / Book	0.05	10.47	10.35	6.24
Net Income	-$48.93M	$2.84B	$3.49B	$358.55M
7 Day Performance	N/A	-0.87%	-0.77%	-1.17%
1 Month Performance	N/A	0.99%	-1.33%	-4.26%
1 Year Performance	N/A	4.14%	21.15%	5.47%

Hepion Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HEPA Hepion Pharmaceuticals	N/A	$0.07 -14.6%	N/A	+22.3%	$772K	N/A	N/A	20	Gap Down
CASI CASI Pharmaceuticals	N/A	$0.21 flat	N/A	N/A	$2.55M	$26.85M	N/A	180
NXTS Nexentis Technologies	1.1928 of 5 stars	$1.69 +1.2%	N/A	-97.3%	$2.45M	$210K	N/A	2	Gap Down
ORGS Orgenesis	N/A	$0.45 +9.1%	N/A	-34.4%	$2.33M	$662K	N/A	150	Gap Up
ATXI Avenue Therapeutics	N/A	$0.65 +20.7%	N/A	-35.2%	$2.15M	N/A	0.04	4	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HEPA) was last updated on 9/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hepion Pharmaceuticals (HEPA) Competitors

HEPA vs. CASI, NXTS, ORGS, ATXI, and JAGX

How does Hepion Pharmaceuticals compare to CASI Pharmaceuticals?

Summary

How does Hepion Pharmaceuticals compare to Nexentis Technologies?

Summary

How does Hepion Pharmaceuticals compare to Orgenesis?

Summary

How does Hepion Pharmaceuticals compare to Avenue Therapeutics?

Summary

How does Hepion Pharmaceuticals compare to Jaguar Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HEPA vs. The Competition

Hepion Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hepion Pharmaceuticals (HEPA) Competitors

HEPA vs. CASI, NXTS, ORGS, ATXI, and JAGX

How does Hepion Pharmaceuticals compare to CASI Pharmaceuticals?

Do analysts rate HEPA or CASI?

Do insiders & institutionals have more ownership in HEPA or CASI?

Which has better earnings & valuation, HEPA or CASI?

Does the media prefer HEPA or CASI?

Which has more volatility & risk, HEPA or CASI?

Is HEPA or CASI more profitable?

Summary

How does Hepion Pharmaceuticals compare to Nexentis Technologies?

Which has stronger earnings & valuation, NXTS or HEPA?

Do insiders and institutionals believe in NXTS or HEPA?

Is NXTS or HEPA more profitable?

Do analysts recommend NXTS or HEPA?

Which has more volatility and risk, NXTS or HEPA?

Does the media refer more to NXTS or HEPA?

Summary

How does Hepion Pharmaceuticals compare to Orgenesis?

Which has more risk and volatility, ORGS or HEPA?

Does the media prefer ORGS or HEPA?

Do institutionals and insiders believe in ORGS or HEPA?

Which has higher valuation & earnings, ORGS or HEPA?

Is ORGS or HEPA more profitable?

Summary

How does Hepion Pharmaceuticals compare to Avenue Therapeutics?

Is ATXI or HEPA more profitable?

Does the media favor ATXI or HEPA?

Which has better valuation & earnings, ATXI or HEPA?

Do institutionals and insiders believe in ATXI or HEPA?

Which has more risk & volatility, ATXI or HEPA?

Summary

How does Hepion Pharmaceuticals compare to Jaguar Animal Health?

Does the media prefer JAGX or HEPA?

Which has higher earnings and valuation, JAGX or HEPA?

Do institutionals & insiders hold more shares of JAGX or HEPA?

Do analysts rate JAGX or HEPA?

Which has more volatility & risk, JAGX or HEPA?

Is JAGX or HEPA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HEPA vs. The Competition

Hepion Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools